Inclusion Criteria:

• Diagnosed with T2D greater than or equal to (≥) 180 days prior to the day of screening.
• Treatment with any of the following non-insulin glucose-lowering medication(s) or combination regimen(s) at the time of screening:

Metformin, Sulfonylureas, Meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs), Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists and Injectable dual glucose-dependent insulinotropic polypeptides (GIP) and GLP-1 receptor agonist.

• Need of intensification with basal insulin, as indicated at the discretion of the investigator.
• Recorded HbA1c value ≥7% within the last 90 days prior to randomization.

Exclusion Criteria:

• Known or suspected hypersensitivity to study intervention(s) or related products.
• Previous participation in this study. Participation is defined as signed informed consent.
• Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method.
• Participation (i.e., received any study intervention) in any interventional clinical study within 90 days before screening.
• Any disorder which in the investigator's opinion might jeopardize participant's safety.